arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

NeuroPace Inc

NPCE
$13.97 ▼ -0.24 (-1.69%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
27 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

NeuroPace Inc faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $476.4M
Dividend Yield —
Revenue Growth -3.0% ↘
Op. Margin -22.5% ↗
ROIC -5.7% ↗
FCF / Share $-0.12 ↗
Trailing P/E —
Price / Book 40.3x
FCF Yield —
Debt / Equity 4.97
info Valuation on last close. End-of-day price, Sep 24, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$22.83M
↓ -3.0% —
Net Income Profit after all expenses
$-6.69M
↓ -1.5% —
Operating Margin Operating profit as % of sales
-22.5%
↑ +10.7% 11th
FCF / Share Free cash flow per share
$-0.12
↑ +33.8% —
Long-Term Debt Long-term obligations
$59.01M
— 0.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
11
Returns
7
Financial Health ↑
24
Cash Quality ↓
41

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 7 years · 27 quarters